News
Recent breakthroughs in understanding the prostaglandin D2 (PGD2) receptor 1 (DP1) are paving the way for innovative ...
Researchers have revealed the mechanism underlying GPCR function using a GPS nuclear magnetic resonance (NMR) technique.
The discovery of G protein-coupled receptor (GPCR) heteromers has revealed a new level of complexity in their functional characteristics. This review explores a variety of methodologies and live ...
Recent breakthroughs in understanding the prostaglandin D2 (PGD2) receptor 1 (DP1) are paving the way for innovative anti-inflammatory and ...
G protein-coupled receptors (GPCRs) are expressed on the surface of cells and regulate a range of important functions. Because they are involved in so many sensory and physiological processes, ...
Dublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global G ...
Nine (27%) patients had prior anti-BCMA CAR T-cell therapy. Fig 1. Flow diagram. BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; GPRC5D, G protein–coupled receptor, class C group 5 ...
Talquetamab is a T-cell–redirecting bispecific antibody targeting G protein–coupled receptor class C group 5 member D (GPRC5D). 13-15 In the MonumenTAL-1 study, more than 71% of the patients ...
Seeking students to join a new and growing lab that seeks to understand the molecular causes of cancer in order to develop better therapies and improve patient outcomes. Our lab seeks to understand ...
G protein-coupled receptors (GPCRs) are involved in many diseases, yet raising therapeutic antibodies against them is notoriously difficult because the transmembrane receptors contain only short ...
2mon
News Medical on MSNUnderstanding the role of astrocytic G protein-coupled receptors in substance-use disordersA recent study published in Engineering delves into the complex mechanisms of drug addiction, highlighting the crucial role ...
From September 1, 2021, to March 23, 2022, 33 patients were infused with anti-GPRC5D CAR T cells. At a median follow-up of 5.2 months (range, 3.2‐8.9), the overall response rate was 91% (95% CI, 76 to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results